Community protesting demolition of Eastern High School
'The Eastern grads are many in this town,' said Linda Peckham, a member of the Coalition to Preserve Eastern High School and Promote Mental Health. 'There are hundreds and hundreds and hundreds who vote and they are very attached to the building for emotional reasons [and] personal reasons because it's a gorgeous building.'
Eastern High School is nearly a century old, and some people in the Greater Lansing area feel connected to the space. For some, it even runs in the family.
'I have four younger sisters, and we all graduated from Eastern, and even my mother graduated from Eastern,' said Faye Norris, who is also part of the coalition.
The group says they are interested in preserving the West Wing and the auditorium.
'The building is quite dilapidated,' said Margaret Dimond, regional president of U-M Health.
Unfortunately, the building hasn't held up the same way many Quakers' memories have.
'The auditorium has water intrusion, mold, black mold, and the asbestos is everywhere…Anyone going through there should have an N95 mask on,' Dimond continued.
She says that given its current state, saving the space simply isn't an option.
'I don't think they understand that a lot of the water intrusion is behind the walls,' said Dimond.
Dimond says plans have been made to keep and highlight artifacts that could be preserved on the new property.
'That includes the beautiful arches and includes the cupula…Things that are historic, we can put around the park,' she said.
The coalition is hoping for the city to do a preservation analysis.
'We're trying to get the mayor to pause the demolition long enough to have that analysis made,' said Peckham.
The group also says they understand and support the need for a new mental health facility
'[They] say we're not interested in mental health, we're only interested in preserving an old building… No. Not true,' said Peckham.
Thursday morning, Lansing Mayor Andy Schor gave 6 News a statement saying if Sparrow meets all the requirements, the city has to issue the permit to allow for demolition.
The city added that if it were to intervene in the project, a lawsuit would likely follow—costing taxpayers money and still resulting in the demolition of Eastern High School.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
- In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. - Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and treatable side effects occurred in most patients treated with Allocetra™ - Webinar today at 8:00 a.m. Eastern Time Nes-Ziona, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 'Company'), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, 'We are excited to share the topline three-month data from ENX-CL-05-001. We believe these results provide clear indication that Allocetra™ has the potential to become a novel, safe and effective treatment for knee osteoarthritis, a growing market with significant unmet medical need.' The Company will host a webinar today at 8:00 am Eastern Time to provide in-depth analysis of the results. To join the webinar, please click To join the webinar, please register at: It is suggested participants join the webinar at least 15 minutes prior to the scheduled start time to avoid any delays in attendance. About ENX-CL-05-001ENX-CL-05-001 is a multi-center Phase I/II clinical trial consisting of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and injection regimen for the subsequent Phase IIa stage. The Phase IIa stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol was designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50 patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation of the total group and specifically to identify a potential responder sub-group. The trial's key efficacy endpoints evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months post treatment. ABOUT KNEE OSTEOARTHRITIS Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint. ABOUT ENLIVEX Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'would,' 'could,' 'intends,' 'estimates,' 'suggests,' 'target,' 'has the potential to' and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Therapeutics, INVESTOR RELATIONS CONTACT Dave Gentry, CEORedChip Companies Inc.1-407-644-4256ENLV@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
How 9 minutes of daily HIIT may improve kids' brain function and learning, according to research
When you buy through links on our articles, Future and its syndication partners may earn a commission. Kids' attention spans aren't exactly getting any longer. Some can't even make it to the end of a 10-second TikTok without swiping away. To be honest, I'm also guilty of this sometimes. But if you can hold their focus for nine whole minutes of exercise, scientists think they've found a little hack that could help children concentrate better in class. Researchers from the University of Eastern Finland studied how short bursts of physical activity could influence a child's ability to focus. They asked seven- to 13-year-olds to complete a simple nine-minute workout before sitting down to cognitive tests. The results? Kids who exercised performed better on tasks that required sustained attention and working memory compared to those who stayed seated. If you are a parent looking to move more and encourage your children to do the same, our guide to the best fitness trackers can help you keep track of your activity levels and stay motivated. What kind of exercise did the study use? The study found that nine minutes of high-intensity interval exercise (HIIE) can help children focus better and improve performance on cognitive tasks. For reference, this activity took place in a school setting before tests. The researchers suggest the boost in focus may come from the temporary increase in heart rate and blood flow, which delivers more oxygen and nutrients to the brain, along with the release of neurotransmitters that support alertness and cognitive function. If you are a parent and want to try using this at home to help your child focus, settle down after school, or tackle homework more easily, the principle is pretty flexible. You don't need a full PE class. Just nine minutes of fun, energetic high-intensity interval exercise (HIIE) that gets your child's heart rate up could make a difference. This could be a quick dance to a favorite song or two, a short obstacle course in the living room, or a few laps around the yard. It's important to note that this research does not provide a guaranteed solution for improving focus in all children, and every child's needs and circumstances are different. The study shows a potential benefit in a classroom setting, but individual results may vary. Still, making exercise a fun and regular part of family life can support both the body and mind. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Here are 7 ways I get the most out of my Garmin watch when training for a race I do this quick chair exercise every day to beat back pain and strengthen my core while I work Forget running — I added power walking intervals to my walks and now I'm hooked Solve the daily Crossword
Boston Globe
3 days ago
- Boston Globe
Rabbits with ‘horns' in Colorado are being called ‘Frankenstein bunnies.' Here's why.
The virus likely influenced the centuries-old jackalope myth in North America, which told of a rabbit with antlers or horns, among other animal variations. The disease in rabbits also contributed to scientists' knowledge about the connection between viruses and cancer, such as the human papillomavirus that causes cervical cancer. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up This photo provided by the Iowa Department of Natural Resources shows a deceased Eastern cottontail rabbit infected with Shope papillomavirus in October 2021. Uncredited/Associated Press Advertisement The virus in rabbits was named after Dr. Richard E Shope, a professor at The Rockefeller University who discovered the disease in cottontails in the 1930s. News about the rabbit sightings in Fort Collins, 65 miles north of Denver, started getting attention after residents started spotting them around town and posting pictures. Kara Van Hoose, a spokesperson for Colorado Parks and Wildlife, told The Associated Press on Wednesday that the agency has been getting calls about the rabbits seen in Fort Collins. But she said that it's not uncommon to see infected rabbits, especially in the summer, when the fleas and ticks that spread the virus are most active. The virus can spread from rabbit to rabbit but not to other species, including humans and pets, she said. Advertisement The growths resemble warts but can look like horns if they grow longer, Van Hoose said. The growths don't harm rabbits unless they grow on their eyes or mouths and interfere with eating. Rabbits' immune systems are able to fight the virus and, once they do, the growths will disappear, she said. ___ Finley reported from Norfolk, Virginia.
